Shilpa Medicare
- Market cap
- ₹ 16,897 Cr.
- P/E
- 64.1x
- P/B
- 6.5x
- 52-week range
- 259.5 – 1,095
- ROE
- 9%
- ROCE
- 11%
- Dividend yield
- 0.1%
- Debt / equity
- 0.25
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Shilpa Medicare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)64.1 against a typical 34.3: pricier than most peers (1st = cheapest).170th of 220
- Sales growth+45.2% against a typical +15.6% from a year earlier.34th of 197
- Profit growth+114.9% against a typical +18.9% from a year earlier.28th of 160
- Share price, 3 months+53.8% against a typical −0.5%.11th of 200
- Size₹ 16,896.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).28th of 199
Latest announcements
Exchange filings and their impact on the company.
- Unit 4 Jadcherla secured EU GMP certification, opening Europe for its sterile injections and oral solids.
Shilpa Medicare said its Unit 4 at Jadcherla, Telangana was inspected by AGES, Austria from 27-30 July 2026 and has now received EU GMP certification. The unit makes sterile injections and non-sterile tablets and capsules for Europe and rest-of-world markets. The approval clears the site for commercial supplies to Europe, supporting export growth over the next year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA-; IND A1+ | Stable | 6 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 6 Jul 2026 | ▲ Upgrade | IND AA- | — | India Ratings | ₹ 110 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Aug 2026 | Financial Results | To consider and approve the Unaudited financial results for the period ended Jun 30, 2026 |
| 22 May 2026 | Financial Results/Dividend | To consider and approve the Audited Standalone and Consolidated Financial Results for the fourth quarter and year ended on March 31, 2026, along with Audit Report of the StatutoryAuditors thereon and declaration of dividend, if any. |
| 6 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 26 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 |
| Expenses | 255 | 222 | 222 | 222 | 258 | 239 | 252 | 231 | 262 | 296 | 317 | 330 |
| Operating Profit | 58 | 65 | 70 | 70 | 86 | 81 | 79 | 91 | 108 | 114 | 120 | 136 |
| OPM % | 19% | 23% | 24% | 24% | 25% | 25% | 24% | 28% | 29% | 28% | 27% | 29% |
| Other Income | 2 | 2 | 9 | 10 | 5 | 2 | −21 | 6 | 2 | −13 | 45 | 9 |
| Interest | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 | 11 | 14 | 12 |
| Depreciation | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 | 30 | 31 | 35 |
| Profit before tax | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 | 61 | 120 | 98 |
| Tax % | 83% | 67% | 12% | 51% | 51% | 24% | 5% | 5% | 32% | 27% | 10% | −3% |
| Net Profit | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 |
| EPS in Rs | 0.09 | 0.26 | 1.41 | 0.72 | 0.92 | 1.62 | 0.74 | 2.4 | 2.25 | 2.28 | 5.51 | 5.16 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 8%
- 5 Years
- 11%
- 3 Years
- 14%
- TTM
- 28%
- 10 Years
- 8%
- 5 Years
- 17%
- 3 Years
- 107%
- TTM
- 117%
- 10 Years
- 11%
- 5 Years
- 23%
- 3 Years
- 64%
- TTM
- —
- 10 Years
- 6%
- 5 Years
- 4%
- 3 Years
- 5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Shilpa Medicare | ₹ 930.00 | ₹ 16,897 Cr. | 64.1x | 6.5x | 9% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Alpesh Maheshkumar Dalal
- Chief Financial Officer
- Ritu Tiwary
- Compliance Officer, Company Secretary
- Vishnukant Chaturbhuj Bhutada
- Managing Director, Executive Director
- Kalakota Sharath Reddy
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.